A Tiny Radioactive Tile Implanted During Brain Surgery Is Changing Cancer Treatment

One Man's Battle — and a Breakthrough Hiding in Plain Sight

Anthony Parise of Beaver County had already endured multiple surgeries and multiple rounds of traditional radiation therapy to fight his brain tumors — only to watch them come back. For patients like him, the cycle of treatment and recurrence is exhausting and devastating. But a small, postage-stamp-sized implant is now offering a fundamentally different approach — one that doesn't make patients wait.

Neurosurgical oncologists at Allegheny General Hospital (AGH), the flagship medical center of Allegheny Health Network (AHN), became the first in the Pittsburgh region to use a novel radiation-emitting implant to treat patients with life-threatening recurrent brain tumors. Parise was the first patient to receive the new treatment at AGH. The device at the center of it all is called GammaTile — and the clinical data behind it is turning heads across oncology.

How GammaTile Works — and Why Timing Is Everything

GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. It is placed directly into the surgical cavity at the time of tumor removal, providing immediate, localized treatment. That timing is the entire point. The standard approach requires a recovery period before radiation can begin, during which remaining microscopic tumor cells may regrow.

GammaTiles target remaining tumor cells immediately once deployed. And because the tile keeps the cesium seeds securely in place while the radiation is released, the therapy occurs while the patient is out of the hospital, going about their daily life. The implant is similar in function to the radioactive seed brachytherapy treatment now commonly used for cancers of the prostate and breast. In other words, this isn't science fiction — it's an adaptation of a proven concept applied to one of medicine's hardest problems.

The Clinical Trial Results That Are Rewriting the Playbook

The Phase III ROADS clinical trial, a multicenter randomized study evaluating GammaTile therapy for patients undergoing surgery for newly diagnosed brain metastases, found that patients who received surgery with GammaTile therapy demonstrated superior tumor control and lived longer without recurrence compared to the current standard of care. Key findings were presented as a late-breaking presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The numbers are striking. Two-year overall survival improved from 35.7% with standard treatment to 61.7% among patients receiving GammaTile. Surgical bed recurrence at one year was reduced from 11.9% with standard therapy to just 1.0% with GammaTile. Perhaps most reassuringly, these results came without a differentiating toxicity profile — radiation necrosis, leptomeningeal disease, adverse events, and quality-of-life scores were statistically comparable between the two treatment arms. Better outcomes, without added harm.

What This Means for Brain Cancer Patients Going Forward

AHN's Neuroscience Institute is now one of just two neurosurgery centers in Pennsylvania using the technology — a sign that access is still limited, but growing. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings.

For Anthony Parise, the treatment represents something beyond statistics — it's a chance at more time. His story puts a human face on data that could soon reshape how oncologists approach every operable brain tumor case. Results from the ROADS trial support GammaTile as a new standard of care for achieving optimal outcomes in this patient population. If that shift happens, the waiting period that has long defined brain cancer treatment — the dangerous gap between surgery and radiation — may become a thing of the past.